Literature DB >> 20191574

Prediction of nonspecific side effects in rheumatoid arthritis patients by beliefs about medicines.

Yvonne Nestoriuc1, E John Orav, Matthew H Liang, Robert Horne, Arthur J Barsky.   

Abstract

OBJECTIVE: This study examines the determinants of patients' side effects from arthritis medication. Proposed predictors were patients' beliefs about medications, objective disease activity, treatment regimen, and psychiatric and rheumatoid arthritis symptoms.
METHODS: In a longitudinal design, 100 rheumatoid arthritis outpatients were investigated at baseline and again at 6 months after receiving both pharmacologic and psychosocial treatment.
RESULTS: Multivariate analyses showed no influence of disease status, type of treatment, or psychiatric or arthritis symptoms on side effects. Heightened concerns about arthritis medication at baseline predicted side effects at baseline (partial correlation r = 0.37, P < 0.001) and at 6 months (partial correlation r = 0.25, P < 0.001) after controlling for relevant disease- and treatment-related variables. In a cross-lagged panel analysis, prior experience with side effects from arthritis medication was ruled out as a cause of heightened concerns, indicating that negative beliefs genuinely contribute to side effects. A comparison of patients who did and did not start new medications showed no difference in side effects in patients with positive beliefs about medications, but led to significantly more side effects in patients with negative beliefs.
CONCLUSION: Patients' beliefs about arthritis medications were stable and consistently associated with side effects. Patients with greater concerns about their arthritis medications are at higher risk for developing side effects, especially when starting new drugs. Identifying those patients is important to avoid premature drug discontinuation. Research into cause and preventability of negative attitudes to prescribed medicines is needed.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20191574      PMCID: PMC2940323          DOI: 10.1002/acr.20160

Source DB:  PubMed          Journal:  Arthritis Care Res (Hoboken)        ISSN: 2151-464X            Impact factor:   4.794


  34 in total

1.  Somatic style and symptom reporting in rheumatoid arthritis.

Authors:  A J Barsky; E J Orav; D K Ahern; M P Rogers; S D Gruen; M H Liang
Journal:  Psychosomatics       Date:  1999 Sep-Oct       Impact factor: 2.386

2.  Determinants of compliance with medication in patients with rheumatoid arthritis: the importance of self-efficacy expectations.

Authors:  H Brus; M van de Laar; E Taal; J Rasker; O Wiegman
Journal:  Patient Educ Couns       Date:  1999-01

3.  Incidence and preventability of adverse drug events among older persons in the ambulatory setting.

Authors:  Jerry H Gurwitz; Terry S Field; Leslie R Harrold; Jeffrey Rothschild; Kristin Debellis; Andrew C Seger; Cynthia Cadoret; Leslie S Fish; Lawrence Garber; Michael Kelleher; David W Bates
Journal:  JAMA       Date:  2003-03-05       Impact factor: 56.272

4.  Indomethacin in rheumatoid arthritis: an evaluation of its anti-inflammatory and side effects.

Authors:  P Donnelly; K Lloyd; H Campbell
Journal:  Br Med J       Date:  1967-01-14

5.  Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis.

Authors:  M L Prevoo; M A van 't Hof; H H Kuper; M A van Leeuwen; L B van de Putte; P L van Riel
Journal:  Arthritis Rheum       Date:  1995-01

6.  Validity of single variables and composite indices for measuring disease activity in rheumatoid arthritis.

Authors:  D M van der Heijde; M A van't Hof; P L van Riel; M A van Leeuwen; M H van Rijswijk; L B van de Putte
Journal:  Ann Rheum Dis       Date:  1992-02       Impact factor: 19.103

7.  Patients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness.

Authors:  R Horne; J Weinman
Journal:  J Psychosom Res       Date:  1999-12       Impact factor: 3.006

8.  Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial.

Authors:  Amalia A van Everdingen; Johannes W G Jacobs; Dirk R Siewertsz Van Reesema; Johannes W J Bijlsma
Journal:  Ann Intern Med       Date:  2002-01-01       Impact factor: 25.391

9.  Factors influencing the beliefs of patients with rheumatoid arthritis regarding disease-modifying medication.

Authors:  L J Goodacre; J A Goodacre
Journal:  Rheumatology (Oxford)       Date:  2004-02-17       Impact factor: 7.580

10.  The use of questionnaires for measuring patient-reported side effects of drugs: its importance and methodological challenges.

Authors:  Juliet M Foster; Thys van der Molen; Manfred Caeser; Philip Hannaford
Journal:  Pharmacoepidemiol Drug Saf       Date:  2008-03       Impact factor: 2.890

View more
  36 in total

Review 1.  Guided Imagery for Arthritis and Other Rheumatic Diseases: A Systematic Review of Randomized Controlled Trials.

Authors:  Peter R Giacobbi; Meagan E Stabler; Jonathan Stewart; Anna-Marie Jaeschke; Jean L Siebert; George A Kelley
Journal:  Pain Manag Nurs       Date:  2015-07-11       Impact factor: 1.929

Review 2.  The placebo response in medicine: minimize, maximize or personalize?

Authors:  Paul Enck; Ulrike Bingel; Manfred Schedlowski; Winfried Rief
Journal:  Nat Rev Drug Discov       Date:  2013-03       Impact factor: 84.694

3.  The placebo effect, sleep difficulty, and side effects: a balanced placebo model.

Authors:  Nadine Neukirch; Ben Colagiuri
Journal:  J Behav Med       Date:  2014-08-14

Review 4.  Lessons learned from placebo groups in antidepressant trials.

Authors:  Meike Shedden Mora; Yvonne Nestoriuc; Winfried Rief
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2011-06-27       Impact factor: 6.237

5.  Attribution-Based Nocebo Effects. Perceived Effects of a Placebo Pill and a Sham Magnetic Field on Cognitive Performance and Somatic Symptoms.

Authors:  Renáta Szemerszky; Zsuzsanna Dömötör; Tímea Berkes; Ferenc Köteles
Journal:  Int J Behav Med       Date:  2016-04

6.  [Biosimilars and the nocebo effect].

Authors:  J Braun; S Tsiami; B Buehring; D Kiefer; I Andreica; X Baraliakos; U Kiltz
Journal:  Z Rheumatol       Date:  2020-04       Impact factor: 1.372

7.  Decreasing the Burden of Side Effects Through Positive Message Framing: an Experimental Proof-of-Concept Study.

Authors:  Marcel Wilhelm; Winfried Rief; Bettina K Doering
Journal:  Int J Behav Med       Date:  2018-08

8.  To tell the truth, the whole truth, may do patients harm: the problem of the nocebo effect for informed consent.

Authors:  Rebecca Erwin Wells; Ted J Kaptchuk
Journal:  Am J Bioeth       Date:  2012       Impact factor: 11.229

9.  The role of patient expectancy in placebo and nocebo effects in antidepressant trials.

Authors:  Bret R Rutherford; Melanie M Wall; Andrew Glass; Jonathan W Stewart
Journal:  J Clin Psychiatry       Date:  2014-10       Impact factor: 4.384

10.  Perceived sensitivity to medicines, alcohol interactive toxicity beliefs, and medication adherence among people living with HIV who drink alcohol.

Authors:  Seth C Kalichman; Rob Horne; Harold Katner; Dominica Hernandez
Journal:  J Behav Med       Date:  2018-10-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.